about
Cancer/testis antigens: novel tools for discerning aggressive and non-aggressive prostate cancerPre- and post-operative nomograms to predict recurrence-free probability in korean men with clinically localized prostate cancerPreoperative Multiparametric Magnetic Resonance Imaging Predicts Biochemical Recurrence in Prostate Cancer after Radical ProstatectomyTools for predicting patient-reported outcomes in prostate cancer patients undergoing radical prostatectomy: a systematic review of prognostic accuracy and validity.The value of personalised risk information: a qualitative study of the perceptions of patients with prostate cancer.External validation of multivariable prediction models: a systematic review of methodological conduct and reportingThe effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databasesAnalytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsiesA four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.Clinical risk-stratification for prostate cancer: Where are we, and where do we need to go?Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework.On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data.Prediction models in urology: are they any good, and how would we know anyway?Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature.Critical review of prostate cancer predictive toolsProstate cancer susceptibility variants confer increased risk of disease progression.Outcomes of active surveillance for men with intermediate-risk prostate cancer.Is pathology necessary to predict mortality among men with prostate-cancer?Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.Impact of genotyping on outcome of prostatic biopsies: a multicenter prospective study.Use of nomograms for predictions of outcome in patients with advanced bladder cancer.miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance.The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy.Surgery for high-risk localized prostate cancer.Prediction models in cancer care.Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.Identifying Persons at Highest Risk of Melanoma Using Self-Assessed Risk Factors.A systematic literature review of life expectancy prediction tools for patients with localized prostate cancerStatistical consideration for clinical biomarker research in bladder cancer.Prostate Cancer: Utility of Whole-Lesion Apparent Diffusion Coefficient Metrics for Prediction of Biochemical Recurrence After Radical Prostatectomy.Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling.Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer.Sample size considerations for the external validation of a multivariable prognostic model: a resampling study.Tumor markers in prostate cancer I: blood-based markers.Deriving benefit of early detection from biomarker-based prognostic models.Unmet needs in the prediction and detection of metastases in prostate cancer.Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score.Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogramPrediction of prostate cancer recurrence using quantitative phase imaging: Validation on a general population
P2860
Q26852766-11167A20-C33D-46EA-A9FE-FFADD562A107Q28539777-69398C74-B679-4E09-833A-8C998E9F0878Q28552107-7E56DCA7-062F-4EA7-824C-AD2E29DF967DQ30234092-7032EA84-CE4D-4C3A-BDEE-B3913419C641Q30544850-47E5C416-CE7C-4EF2-BD5F-3AB4DCE1570FQ30577024-B0F20F92-D6DF-4FBE-B485-4D9323521D2FQ33516060-1848A043-AA67-4CAA-A0EC-9A92B3518C5BQ33557377-CF5170DE-4C21-4EE0-8CF6-EE1109D17C58Q33642692-A642E541-53D2-47B7-A429-9A30DDE467ACQ33696654-22E44829-648E-435E-8C7C-95E72B254B41Q33705993-128D9BBB-D4BF-4EA9-A296-D9F574E96748Q33800997-45E6757B-EC57-4967-B042-7625BEC90865Q33870074-C50D0983-E2EB-4B67-818A-55E715E83964Q33940100-419F14F8-FA23-4B03-81D8-D8F516CBC65EQ33993472-3FA2D90E-2A31-43C7-BE05-45BA70491E4DQ34104562-6493DE4A-38AF-4B36-9C99-6D91A738CA18Q34175836-8CAF6492-87B3-4873-9E6A-1BE7A7B868ACQ34679207-D87F9E78-0D7E-4D77-AECD-D29748284F02Q34769040-D1D66834-80CC-40E8-BA4B-AED2C152DD84Q34962331-E4A4AF89-9004-4822-B5CB-8FCB15C4BA0CQ35016946-8611C709-F74F-4A08-B9CD-0FD6A1F21BACQ35076360-4CDDC228-744B-4DC4-9C55-CD29A6D7AFE8Q35180831-D0D0DBBB-45BE-4ACA-AB43-FC0DA3EAB865Q35207309-4D2BDE29-D13C-4985-B48E-979F96BF407EQ35220192-EDF83E59-4E12-48DF-B2BD-B950E55CA858Q35292878-C062219E-3C0F-4BC1-8FA2-595EA8CD6AA1Q35632848-24778C1C-2C1F-4080-95BF-D50349E91EDDQ35655735-77752CBE-2E0E-4A57-853B-1CCBE4A9C4F3Q35852490-09D0BF9B-4638-41C5-8DDA-BDA4139D96BAQ36124883-731DC7F9-5D3B-464A-B51F-411741912578Q36406333-45D02AE6-26D1-4604-824B-DA0DD3C78B7FQ36419132-E7E685DE-8631-433E-9DE3-0FBA0F87C4ABQ36532680-4BA53F06-255B-47A3-8F64-9D98070FEF5DQ36536706-A8F54033-AD91-4194-A767-6252784F87B5Q36607766-C15DE290-9C84-4D5C-A3C9-E6FAB30F03F8Q36623424-2F28588F-6911-40A3-8112-9322A2D14CC6Q36871680-9A38ED5C-EC2F-44E6-9D16-D177328803C9Q37270472-028E2C61-F544-4B8D-B834-6E6A75EB0466Q37274238-A13B7201-0F71-4057-AA2E-E503FE8CD836Q37278199-02445711-E3F8-4C8F-8E1F-5AC6F0BAE673
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
An updated catalog of prostate cancer predictive tools.
@en
An updated catalog of prostate cancer predictive tools.
@nl
type
label
An updated catalog of prostate cancer predictive tools.
@en
An updated catalog of prostate cancer predictive tools.
@nl
prefLabel
An updated catalog of prostate cancer predictive tools.
@en
An updated catalog of prostate cancer predictive tools.
@nl
P2093
P356
P1433
P1476
An updated catalog of prostate cancer predictive tools.
@en
P2093
Claus G Roehrborn
Michael W Kattan
Pierre I Karakiewicz
Shahrokh F Shariat
P304
P356
10.1002/CNCR.23908
P407
P577
2008-12-01T00:00:00Z